PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab

DRUG2 trials

Sponsors

Zhongda Hospital

Conditions

Hepatocellular Carcinoma

Unknown Phase

TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for Advanced HCC

CompletedNCT05332821

Zhongda HospitalHepatocellular Carcinoma

Start: 2022-12-28End: 2024-01-10Updated: 2026-04-17

TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for Intermediate HCC

CompletedNCT05332496

Zhongda HospitalHepatocellular Carcinoma

Start: 2022-12-28End: 2025-09-14Updated: 2026-04-17

Related Papers

Immune checkpoint inhibitors and anti-vascular endothelial growth factor antibody/tyrosine kinase inhibitors with or without transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma (CHANCE2201): a target trial emulation study.

2024-05-06104 citations

Unresectable hepatocellular carcinoma: transarterial chemoembolisation plus Huachansu – a single-center randomised controlled trial

BMJ Supportive & Palliative Care2023-07-038 citations